for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aspen Pharmacare Holdings Limited

APNJ.J

Latest Trade

11,946.00ZAc

Change

-212.00(-1.74%)

Volume

941,481

Today's Range

11,928.00

 - 

12,250.00

52 Week Range

6,407.00

 - 

15,705.00

As of on the Johannesburg Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Aspen Pharmacare Sells Japanese Ops To Sandoz For Up To Eur 400 Mln

Nov 11 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::JSE: APN - DIVESTMENT OF ASPEN’S JAPANESE OPERATIONS.ASPEN PHARMACARE HOLDINGS LTD - PROPOSED DEAL FOR FOR A CASH CONSIDERATION OF UP TO EUR 400 MILLION.ASPEN PHARMACARE HOLDINGS LTD - PROCEEDS FROM TRANSACTION WILL BE USED TO REDUCE DEBT.ASPEN PHARMACARE - UNIT CONCLUDED AN AGREEMENT TO DIVEST OF ITS JAPANESE OPERATIONS AND ANY RELATED INTELLECTUAL PROPERTY TO SANDOZ.ASPEN PHARMACARE HOLDINGS LTD - ADDITIONALLY, AGI HAS ENTERED INTO A FIVE YEAR MANUFACTURING AND SUPPLY AGREEMENT WITH SANDOZ.ASPEN PHARMACARE HOLDINGS LTD - DISPOSAL OF JAPANESE OPERATIONS COMPRISES OF TRANSFER OF ALL OF AGI'S SHARES IN ASPEN JAPAN K.K TO SANDOZ.

Aspen Pharmacare Says In Talks On Selling A Commercial Business In Asia Pacific Region

Nov 8 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::CAUTIONARY ANNOUNCEMENT.CURRENTLY ENGAGED IN DISCUSSIONS REGARDING DIVESTMENT OF A COMMERCIAL BUSINESS IN ASIA PACIFIC REGION.

Aspen Says No Dividend Been Declared For Year

Oct 28 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::SUMMARISED AUDITED GROUP ANNUAL FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2019 AND NOTICE OF AGM.FY NORMALISED HEADLINE EARNINGS PER SHARE FROM CONTINUING OPERATIONS DECREASED BY 7% TO 1 414.3 CENTS.NO DIVIDEND HAS BEEN DECLARED FOR YEAR ENDED 30 JUNE 2019 (JUNE 2018: 315 CENTS)..FY REVENUE FROM CONTINUING OPERATIONS INCREASED BY 1% TO R38.9 BILLION (RESTATED JUNE 2018: R38.3 BILLION).FY EARNINGS PER SHARE INCREASED BY 7% TO 1 415.9 CENTS.FY HEADLINE EARNINGS PER SHARE FROM CONTINUING OPERATIONS DECREASED BY 11% TO 1 227.6 CENTS (RESTATED JUNE 2018: 1 383.5 CENTS).AS A CONSEQUENCE OF ZANTAC RECALL,HAS REVISED ASSUMPTIONS SUPPORTING VALUE OF ZANTAC BRAND AND RAISED AN IMPAIRMENT OF ZAR 719 MILLION.ACTIVELY WORKING ON PLANS TO RELAUNCH ZANTAC CONTAINING ALTERNATIVE API FORMULATION.

UK's CMA Provisionally Finds Aspen Paid Firms To Stay Out Of UK Market For Addison's Disease Drug

Oct 3 (Reuters) - UK's CMA::PROVISIONALLY FOUND THAT 3 DRUG FIRMS SIGNED "ILLEGAL AGREEMENT" THAT RESULTED IN SIGNIFICANT PRICE HIKES FOR AN ESSENTIAL MEDICINE.PROVISIONALLY FOUND THAT ASPEN "UNLAWFULLY" AGREED TO PAY AMILCO AND TIOFARMA TO STAY OUT OF UK MARKET FOR FLUDROCORTISONE ACETATE TABLETS.PROVISIONALLY FOUND TIOFARMA, AMILCO "COLLUDED WITH ASPEN" BY AGREEING TO STAY OUT OF UK MARKET SO ASPEN WAS SOLE SUPPLIER OF FLUDROCORTISONE.SHOULD CMA CONCLUDE THERE WAS AN INFRINGEMENT, ASPEN AGREED TO MAXIMUM PENALTY OF £2.1 MILLION; AMILCO & TIOFARMA HAVE MADE NO ADMISSION.ACCEPTED ASPEN'S OFFER OF COMMITMENTS TO RESOLVE CONCERN ON PURCHASE OF COMPETITOR FLUDROCORTISONE PRODUCT FROM TIOFARMA FOR SUPPLY IN UK.COMMITMENTS INCLUDE ASPEN OFFERING TO PAY NHS £8 MILLION, & ENSURING THAT, IN FUTURE, THERE WILL BE AT LEAST 2 SUPPLIERS OF FLUDROCORTISONE IN UK.

Aspen Pharmacare Says Public Investment Corp Increases Interest In Co

Sept 30 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::JSE: APN - NOTIFICATION IN TERMS OF SECTION 122(3) OF THE COMPANIES ACT.ASPEN PHARMACARE - PUBLIC INVESTMENT CORPORATION SOC NOTIFIED CO IT INCREASED BENEFICIAL INTEREST IN CO'S SECURITIES TO 15.049% EFFECTIVE SEPT 26.

Aspen Pharmacare Posts FY Normalised HEPS From Cont Ops Down 7%

Sept 11 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::GROUP FINANCIAL RESULTS FOR THE YEAR ENDED 30 JUNE 2019.FY REVENUE FROM CONTINUING OPERATIONS INCREASED BY 1% TO R38.9 BILLION.FY NORMALISED HEADLINE EARNINGS PER SHARE FROM CONTINUING OPERATIONS DECREASED BY 7% TO 1 414.3 CENTS.NO DIVIDEND HAS BEEN DECLARED FOR YEAR ENDED 30 JUNE 2019.FY NORMALISED EBITDA FROM CONTINUING OPERATIONS DECREASED BY 2% TO R10.8 BILLION.H2 PERFORMANCE IN 2020 FY IS LIKELY TO BE STRONGER THAN IN H1 OF THAT YEAR.PERFORMANCE FOR 2020 FY TO BE BROADLY IN LINE WITH RESULTS REPORTED FOR 2019.INTENDS TO PURSUE COMMERCIAL OPPORTUNITY OF RECOMMENCING SALE OF HEPARIN TO THIRD-PARTY CUSTOMERS.

Aspen Pharmacare Intends Releasing Results For FY On Sept 11

Sept 9 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::ASPEN’S RESULTS FOR THE YEAR ENDED 30 JUNE 2019 AND RESULTS PRESENTATION.INTENDS RELEASING RESULTS FOR YEAR ENDED 30 JUNE 2019 AFTER MARKET CLOSES ON SEPT 11.

Aspen Pharmacare Sees FY Total HEPS 1,224-1 283 Cents

Sept 3 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::TRADING STATEMENT.SEES FY REPORTED REVENUE GROWTH 0% TO 2.0%.SEES FY TOTAL NHEPS 1 433.6 TO 1 498.1 CENTS.SEES FY CER REVENUE GROWTH -3.0% TO 0%.SEES FY NHEPS FROM CONTINUING OPERATIONS 1 381.8 TO 1 442.5 CENTS.SEES FY TOTAL HEPS 1 224.0 TO 1 283.0 CENTS.SEES FY HEPS FROM CONTINUING OPERATIONS 1 203.7 TO 1 259.0 CENTS.

Aspen Pharmacare Says Coronation Asset Management Increased Beneficial Interest In Co

Aug 23 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::CORONATION ASSET MANAGEMENT NOTIFIED COMPANY THAT IT HAS INCREASED ITS BENEFICIAL INTEREST IN SECURITIES OF COMPANY.CORONATION ASSET MANAGEMENT HOLDS 10.60% OF ORDINARY SHARE CAPITAL OF COMPANY, EFFECTIVE 23 AUGUST.

Aspen Pharmacare Says Allan Gray Now Holds 5.0066% Of Ordinary Share Capital Of Co

Aug 16 (Reuters) - Aspen Pharmacare Holdings Ltd <APNJ.J>::ASPEN PHARMACARE - ALLAN GRAY HOLDS 5.0066% OF ORDINARY SHARE CAPITAL OF CO.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up